Citrate for long-term hemodialysis: prospective study of 1,009 consecutive high-flux treatments in 59 patients.

BACKGROUND Regional citrate anticoagulation during hemodialysis is performed in selected patients at highly specialized units. We postulated that routine use of citrate at a long-term dialysis ward is safe and efficient. METHODS During a 2-year period, we studied 1,009 consecutive citrate-anticoagulated high-flux hemodialysis treatments performed in 59 patients at our long-term dialysis ward. We used a simple citrate infusion protocol, calcium-free dialysate, and intravenous calcium substitution. Simple and clear algorithms allowed adjustments of the calcium substitution rate and dialysate settings by the attending nurse. Adverse events; indications for citrate anticoagulation; clotting; technical data; blood ionized calcium, sodium, and potassium levels; and acid-base homeostasis were analyzed prospectively. RESULTS Of the treatments, 99.6% were accomplished successfully. Two adverse events were attributed to citrate use. Overall, ionized calcium levels were stable during the procedures and electrolyte and acid-base balances were well controlled. The use of central venous catheters for dialysis was associated with paradoxical behavior of ionized calcium levels (increasing blood ionized calcium levels despite decreased calcium infusion). Anticoagulation was excellent. CONCLUSION Routine use of citrate anticoagulation in the setting of a long-term hemodialysis ward is safe and efficient. Measured ionized calcium levels should be interpreted with care if central venous catheters are used for vascular access because they could be biased by recirculation.

[1]  R. Apsner,et al.  Parathyroid Hormone Secretion During Citrate Anticoagulated Hemodialysis in Acutely Ill Maintenance Hemodialysis Patients , 2004, Anesthesia and analgesia.

[2]  Kyu-Beck Lee,et al.  Hemodialysis Using Heparin-Bound Hemophan in Patients at Risk of Bleeding , 2004, Nephron Clinical Practice.

[3]  J. Chanard,et al.  Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  M. Dorval,et al.  A novel citrate anticoagulation regimen for continuous venovenous hemodiafiltration , 2003, Intensive Care Medicine.

[5]  R. Apsner,et al.  Long-term citrate anticoagulation for high-flux haemodialysis in a patient with heparin-induced thrombocytopenia type II. , 2002, Acta medica Austriaca.

[6]  B. Maes,et al.  Regional citrate anticoagulation for hemodialysis using a conventional calcium-containing dialysate. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  Thomas Lang,et al.  Simplified citrate anticoagulation for high-flux hemodialysis. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  R. Apsner,et al.  Dalteparin-induced alopecia in hemodialysis patients: reversal by regional citrate anticoagulation. , 2001, Blood.

[9]  J. van Limbeek,et al.  Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  T. Matsuo,et al.  Heparin-induced thrombocytopenia in hemodialysis patients. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  L. Pillsbury,et al.  Regional hemodialysis anticoagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  J. Deegens,et al.  Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients. , 1996, Kidney international.

[13]  W. Hörl,et al.  Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation. , 1996, Journal of the American Society of Nephrology : JASN.

[14]  À. Argilés,et al.  Calcium balance and intact PTH variations during haemodiafiltration. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  M. Prins,et al.  Low molecular weight heparin: a critical analysis of clinical trials. , 1994, Pharmacological reviews.

[16]  J. Hirsh Low molecular weight heparin , 2007 .

[17]  J. Oliver,et al.  Normalization of uremic acidosis in hemodialysis patients with a high bicarbonate dialysate. , 1993, Journal of the American Society of Nephrology : JASN.

[18]  P. Kerr,et al.  Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. , 1993, Kidney international.

[19]  J. Hirsh,et al.  Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. , 1992, Chest.

[20]  J. van der Meulen,et al.  Citrate anticoagulation and dialysate with reduced buffer content in chronic hemodialysis. , 1992, Clinical nephrology.

[21]  B. Materson,et al.  Metabolic alkalosis induced by regional citrate hemodialysis. , 1989, ASAIO transactions.

[22]  G. Schulman,et al.  Severe metabolic alkalosis complicating regional citrate hemodialysis. , 1987, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  M. Flanigan,et al.  Reducing the hemorrhagic complications of hemodialysis: a controlled comparison of low-dose heparin and citrate anticoagulation. , 1987, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  A. Hocken,et al.  Citrate regional anticoagulation in haemodialysis. , 1987, Nephron.

[25]  M. Flanigan,et al.  Regional anticoagulation: hemodialysis with hypertonic trisodium citrate. , 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  B. Danielson,et al.  Magnesium studies in hemodialysis patients before and after treatment with low dialysate magnesium. , 1984, Nephron.

[27]  D. Diederich,et al.  Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. , 1983, The New England journal of medicine.

[28]  D. S. Hall,et al.  REGIONAL ANTICOAGULATION DURING HEMODIALYSIS USING CITRATE , 1961, The American journal of the medical sciences.